Lexology September 4, 2024
McGuireWoods Consulting LLC

Click here to listen to the audio.

A revolution in the use of psychedelic drugs to treat mental health issues experienced a setback in early August when the FDA declined to approve MMDA as a treatment for post-traumatic stress disorder.

Host Stephanie Kennan provides important context to the FDA’s decision, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
Unlocking The Genetic Code: AI Reveals New Insights Into Psychiatric Disorders
The Future of Behavioral Health Delivery
Fixing the Growing Payer-Provider Divide in Behavioral Health
Workers Feel “Stuck,” Under-Insured, Financially Stressed, and Neglecting Mental Health
Franciscan Health to convert hospital to behavioral health facility

Share This Article